



# Long-Acting Injectable HIV Treatment Is Effective in Diverse Populations Worldwide

European AIDS Conference; October 15-18, 2025; Paris, France  
Poster eP103  
Presenting author: Chloe Orkin; c.m.orkin@qmul.ac.uk

## How does HIV affect the body?

Human immunodeficiency virus (HIV) makes copies of itself throughout the body and kills the CD4 cells that fight off infections

## How can treatment help?

HIV medicines can slow or stop the virus from making copies of itself, preventing CD4 cells from being killed

## What treatment was studied here?

- A long-acting (LA) treatment consisting of the 2 injectable drugs, cabotegravir (CAB) and rilpivirine (RPV), given either every month or every 2 months as intramuscular injections

## What was the purpose of this study?

- Many independent studies have been conducted worldwide on people with HIV being treated with CAB + RPV LA in real-life clinical practice
- We want to analyze these studies all together to better understand how well treatment works to suppress HIV levels in people and how well they tolerate the medication

## What data was included?


- We used a research method called a systematic literature review to find published abstracts and articles about these studies
- Through a method called a meta-analysis, we then looked at different aspects of how well CAB + RPV LA worked when these studies were grouped together
- Our analyses included diverse populations from 27 studies of 7687 people with HIV who were virologically suppressed (<50 virus copies per mL of blood) who had switched to CAB + RPV LA conducted in a variety of countries
- Not all studies were included in each individual analysis




Australia  
Canada  
France  
Germany  
Italy

Japan  
Spain  
United Kingdom  
United States

## How effective was CAB + RPV LA by Month 12 of treatment?



## How many people stopped CAB + RPV LA treatment by Month 12?



<sup>a</sup>Injection site reactions refer to physical reactions (such as swelling, pain, or redness) that occur at the site the injection was administered.

## Did people receiving CAB + RPV LA follow their treatment schedule?



## What does this mean for people living with HIV?

- In real-world clinical settings, people receiving CAB + RPV LA maintained high rates of virologic suppression at Month 12
- Following the switch to CAB + RPV LA, people experienced low rates of virologic failure and resistance at Month 12
- A low percentage of people stopped treatment, including due to injection site reactions



### Poster presentation title:

Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living With HIV-1: A Meta-Analysis of Real-World Evidence

### Authors:

Chloe Orkin<sup>1</sup>, William R. Short<sup>2</sup>, Irina Kolobova<sup>3</sup>, Natalya Danchenko<sup>3</sup>, Inês Augusto<sup>4</sup>, Kimberley Brown<sup>3</sup>, Marius Sieverding<sup>5</sup>, Matthew Turner<sup>6</sup>, Steffan Hill<sup>6</sup>, Ian Jacob<sup>7</sup>

<sup>1</sup>Queen Mary University of London, London, United Kingdom; <sup>2</sup>Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States; <sup>3</sup>ViiV Healthcare, Durham, NC, United States; <sup>4</sup>ViiV Healthcare, Algés, Portugal; <sup>5</sup>GSK, London, United Kingdom; <sup>6</sup>HEOR Ltd, Cardiff, United Kingdom; <sup>7</sup>ViiV Healthcare, London, United Kingdom

## Disclaimer

**This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.**